Quick Answer
AIM ImmunoTech Inc. reported Diluted EPS of $8.62 per share (loss) for fiscal year 2025.
AIM ImmunoTech Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$8.62 | +72.1% |
| 2024 | -$30.92 | -5053.3% |
| 2023 | -$0.60 | -50.0% |
| 2022 | -$0.40 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.57 | +126.2% | +142.7% |
| June 30, 2025 | -$3.68 | -22.7% | -7260.0% |
| March 31, 2025 | -$0.05 | +58.3% | +99.2% |
| September 30, 2024 | -$6.00 | -3650.0% | -100.0% |
| June 30, 2024 | -$3.00 | -2900.0% | -2400.0% |
| March 31, 2024 | -$0.12 | -50.0% | +25.0% |
| September 30, 2023 | -$0.16 | -23.1% | -60.0% |
| June 30, 2023 | -$0.10 | +0.0% | -25.0% |
- AIM ImmunoTech Inc. showed an increase of +72.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, AIM ImmunoTech Inc.’s diluted eps has declined by 2055.0% (from $0.40 per share (loss) to $8.62 per share (loss)).
- The most recent figure is from AIM ImmunoTech Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: